CA-DRISHTI-TECHNOLOGIES
24.3.2022 11:02:14 CET | Business Wire | Press release
Drishti Technologies, Inc. (Drishti), whose AI-powered manufacturing technology uses video analytics, data and insights to bring significant benefits to manufacturers and their employees, and HELLA (FRA:HLE) a tier-one automotive supplier, today announced the latest in a joint effort to further increase operational efficiency with a second successful combined project in Dhankot, India. HELLA is an internationally positioned automotive supplier globally recognized for its lean practices and is committed to investing in the latest technologies to drive human productivity and improve manufacturing outcomes.
With Drishti cameras and streaming video analysis enabled on one of HELLA’s sensor product lines, the HELLA team made a series of previously concealed discoveries. First, the massive volume of cycle time data available from Drishti quickly revealed slowdowns in stations that were not originally the focus of improvement efforts. Second, by watching video footage from the identified station, the team understood that the physical station configuration was slowing down the line associates.
In fact, the station setup was causing ergonomic concerns. Because the line associate was reaching with his right arm across to the left side of the station, each cycle required a twisting motion that led to fatigue.
“Because our focus had been on the station we thought was the bottleneck, we had overlooked this potential for slowdowns and fatigue,” said Ram Singh Khangarote, operational excellence and operation product manager, HELLA Dhankot. “Within a few minutes of viewing the video footage from Drishti, our team had ideas to reconfigure the station to make it more comfortable for the line associates, and shortening every cycle time. And most importantly, our line associates are healthier, happier and more productive.”
Finally, with Drishti, because the team in Dhankot learned the true cause of line slowdowns, they were able to improve line balancing. The Drishti investment paid for itself in less than six months.
“This is the second instance of finding significant improvement opportunities using Drishti. In 2020, we reduced cycle times in our Guanajuato, Mexico plant . Now we’re seeing value in Dhankot, as well,” said Huri Mendoza, head of operational excellence, HELLA. “Drishti’s technology perfectly complements our goal of achieving operational excellence by augmenting our extremely capable workforce and empowering them with the tools they need to perform their jobs even better.”
The Dhankot plant deployment is one of several ongoing collaborations between HELLA and Drishti. Drishti streams video at every station on a line, then uses proprietary AI networks to translate video streams into data, a technique called action recognition. The line-level data on cycles and actions helps manufacturers improve productivity and quality while improving standardized work adherence.
“Drishti’s action recognition technology provides manufacturers with a clear competitive edge, as they can see improvement opportunities on assembly lines that are otherwise hidden,” said Gary Jackson, CEO, Drishti. “HELLA’s success with Drishti is in line with what we’re seeing across the automotive industry, as well as in other verticals like electronics and medical devices. The future of automated video analysis, which creates insights on people at work, runs through Drishti.”
About Drishti
Drishti’s AI-powered video analytics technology augments human workers and provides visibility and insights that transform the pace and impact of manual assembly line improvement. Manufacturers use Drishti to anchor true digital transformation, driving sweeping improvements in quality costs, efficiency gains & time-to-proficiency for line associate training. And line associates rely on Drishti to be more consistent and efficient, becoming even more valuable on the factory floor. Drishti has been recognized as a World Economic Forum Technology Pioneer and a Forbes AI 50 company, among others. For more information, visit drishti.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
